Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
PhRMA Issues Principles on Investigator-Initiated Studies, Urges Drug Makers Not to Offer Labor
The Pharmaceutical Research and Manufacturers of America, better known as PhRMA, issued its basic principles on drug makers’ support for investigator-initiated studies on March 11, urging them not to take part in protocol designs or extend labor such as data…
To read the full story
Related Article
ORGANIZATION
- Off-Year Drug Price Revisions Run Counter to Innovation, JPMA Exec Says
January 23, 2026
- Kobe, iPark Institute, Partners Sign Pact to Accelerate Innovation at KBIC
January 21, 2026
- OTC Industry Head Urges Caution on Extra Charges for “OTC-Like” Drugs
January 20, 2026
- JETRO Picks 10 Overseas Startups for Regenerative Medicine Japan Entry Program
January 20, 2026
- Pharma FTC Clarifies “Simple Beverages” under New Food Rules
January 14, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…